AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

IRBESARTAN 300 Mg ;

12 registrations across 1 African market— 12 active

Markets with IRBESARTAN 300 Mg ;

Recent registrations

Brand / ProductMarketHolderStatusExpires
APROVEL® 300mg
Film Coated Tablets
🇪🇬EgyptSANOFI scientific officeactive
APROVEL® 300mg
Film Coated Tablets
🇪🇬EgyptSANOFI scientific officeactive
Angioblock Mono 300 mg
Tablets
🇪🇬EgyptGlobal Advanced pharmaceuticals "GAP"active
Irbesartan 300 mg
Film Coated Tablets
🇪🇬EgyptArab Company for Pharmaceuticals and Medicinal Plants _ Mepaco- Medi Foodactive
Irbedrin ® 300 mg
Tablets
🇪🇬EgyptMedical Union Pharmaceuticals - MUPactive
Kansartan 300 mg
Tablets
🇪🇬EgyptChemipharm Pharmaceutical Industriesactive
X –Tension 300 mg
Tablets
🇪🇬EgyptThe Tenth of Ramadan for Pharmaceutical Industries & Diagnostic Reagents "RAMEDA"active
Angioblock Mono 300 mg
Tablets
🇪🇬EgyptGlobal Advanced pharmaceuticals "GAP"active
Irbesartan 300 mg
Film Coated Tablets
🇪🇬EgyptArab Company for Pharmaceuticals and Medicinal Plants _ Mepaco- Medi Foodactive
Kansartan 300 mg
Tablets
🇪🇬EgyptChemipharm Pharmaceutical Industriesactive
X –Tension 300 mg
Tablets
🇪🇬EgyptThe Tenth of Ramadan for Pharmaceutical Industries & Diagnostic Reagents "RAMEDA"active
Irbedrin ® 300 mg
Tablets
🇪🇬EgyptMedical Union Pharmaceuticals - MUPactive

IRBESARTAN 300 Mg ; in Africa — Regulatory Overview

IRBESARTAN 300 Mg ; is registered across 1 African markets with 12 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Egypt. AfricaRegulatory refreshes this data daily from official government sources.

Of the 12 registrations, 12 (100%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.